• Zolmitriptan as a 5-HT1B Receptor Agonist for Migraine Resea

  2026-04-30

  Zolmitriptan is a selective 5-HT1B/1D/1F serotonin receptor agonist widely utilized in migraine research. Its mechanism involves cranial vasoconstriction and inhibition of neuropeptide release, supporting its use as a robust research compound for studying migraine and cluster headaches. APExBIO provides high-purity Zolmitriptan (B2261) with validated solubility and handling parameters.

• Proximity Labeling Reveals Dynamic Synaptic Protein Traffick

  2026-04-30

  Pascual-Caro and de Juan-Sanz (2024) introduce a rapid, synaptic cleft-targeted proximity labeling technique that enables the quantification of activity-driven trafficking of endogenous synaptic proteins. This approach overcomes previous limitations in resolving the transient surface exposure of vesicular proteins during neuronal activity and provides new insights into synaptic molecular dynamics.

• Berberine Hydrochloride: Mechanistic Insights & Protocols

  2026-04-29

  Berberine hydrochloride is a potent AMPK activator with antibacterial and metabolic regulatory properties. It modulates lipid metabolism, upregulates LDL receptors, and suppresses anti-apoptotic proteins in cancer research. This article delivers evidence-based benchmarks and actionable protocols for metabolic and cardiovascular disease models.

• SR-202 (PPAR Antagonist): Mechanistic and Benchmark Dossier

  2026-04-29

  SR-202, a selective PPARγ antagonist, inhibits PPAR-dependent adipogenesis and improves insulin sensitivity in preclinical models. This article details its specificity, utility in metabolic research, and mechanistic benchmarks, with verifiable citations. Applications in obesity and type 2 diabetes research are critically examined.

• Miltefosine: Optimizing Neutrophil Differentiation via PI3K/

  2026-04-28

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) uniquely modulates both PI3K/Akt and Ras/MEK/ERK pathways to drive neutrophil differentiation and cell survival, offering translational leverage for hematology and oncology research. This guide distills workflow optimizations, troubleshooting, and protocol decisions to maximize the molecule’s impact in bench-to-bedside applications.

• Optimizing Forensic Detection with DFO (9H-1,8-Diazafluoren-

  2026-04-28

  This article provides a scenario-driven, evidence-based guide to leveraging DFO (9H-1,8-Diazafluoren-9-one) (SKU C6997) for sensitive, reproducible latent fingerprint detection on porous substrates. Researchers and lab technicians will find practical workflow insights and protocol parameters that enhance reliability and interpretability, especially when working with amino acid-reactive fluorescent dyes in forensic applications.

• Primidone and Aromatase: Evidence for Selective Enzyme Inter

  2026-04-27

  Jacobsen et al. (2008) systematically evaluated the inhibitory effects of twelve antiepileptic drugs on human aromatase (CYP19), clarifying their potential impact on steroidogenesis and associated endocrine outcomes. Notably, Primidone (Mysoline) exhibited no inhibition of aromatase activity, distinguishing it from several commonly used AEDs and supporting its use where hormonal side effects are a concern.

• GDC-0941: Protocols and Advances in PI3K Inhibitor Research

  2026-04-27

  GDC-0941 sets the benchmark for selective PI3K/Akt pathway inhibition, empowering researchers to dissect oncogenic signaling and overcome resistance in cancer models. This guide provides step-by-step workflows, data-driven troubleshooting, and actionable insights for maximizing GDC-0941’s translational impact.

• Oral CXCR4 Antagonist Mavorixafor in WHIM Syndrome: Phase 3

  2026-04-26

  A recent placebo-controlled phase 3 trial demonstrates that oral mavorixafor, a selective CXCR4 antagonist, effectively increases neutrophil and lymphocyte counts while reducing infection rates in patients with WHIM syndrome. This study highlights a significant advance in treating a rare immunodeficiency by directly targeting the underlying CXCR4/CXCL12 signaling pathway.

• Bufalin: Cardiotonic Steroid Workflows in Cancer Research

  2026-04-25

  Bufalin, a cardiotonic steroid from APExBIO, enables high-precision apoptosis induction and targeted protein degradation in triple-negative breast cancer and hepatocellular carcinoma models. This guide translates the latest STK33-targeting breakthroughs and experimental best practices into actionable, reproducible workflows for oncology labs.

• L-Ornithine: Mechanistic Leverage for Translational Metaboli

  2026-04-24

  This article provides translational researchers with a strategic, evidence-driven perspective on L-Ornithine’s role in bridging hepatic nitrogen disposal with neuro-metabolic regulation. Drawing from recent mechanistic insights into the urea cycle, CNS toxicity, and astrocyte glycolysis, it outlines how high-purity L-Ornithine from APExBIO enables reproducible, cross-system experimental models. The article advances beyond standard product pages by integrating pivotal literature, practical assay guidance, and outlooks on translational impact.

• SNS-032 (BMS-387032): Enhancing CDK Inhibition Workflows

  2026-04-24

  SNS-032 (BMS-387032) empowers researchers with selective, reproducible inhibition of CDK2, CDK7, and CDK9 for advanced cancer and antiviral studies. Its validated performance in cell cycle, apoptosis, and transcriptional control assays enables confident experimental design and troubleshooting.

• DNA Damage Sensing and TP53: Modulators of Calicheamicin ADC

  2026-04-23

  This study uses genome-wide CRISPR/Cas9 screening to identify DNA damage response genes, including TP53, ATM, and MDM2, as key determinants of sensitivity to calicheamicin-based antibody–drug conjugates (ADCs) in acute leukemia. The findings highlight mechanisms of resistance and support further exploration of combination therapies targeting these pathways.

• AURKB Inhibition as a Therapeutic Strategy in Pulmonary Hype

  2026-04-23

  Lemay et al. (2025) identify Aurora kinase B (AURKB) as a driver of pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension (PAH). Through integrated transcriptomics and preclinical validation, the study demonstrates that selective AURKB inhibition reverses vascular remodeling and improves hemodynamics, highlighting a novel molecular target for PAH intervention.

• Dorsomorphin (Compound C): Applied AMPK Inhibition for Advan

  2026-04-22

  Dorsomorphin (Compound C) empowers precise modulation of AMPK and BMP pathways for dissecting metabolism, autophagy, and differentiation in cellular and animal models. This guide delivers actionable protocols, highlights troubleshooting for solubility and specificity, and bridges the latest mechanistic insights—ensuring reliable results with APExBIO’s gold-standard reagent.

14939 records 1/996 page Next 12345 下5页 Last page